LeMaitre Vascular vs PROCEPT BioRobotics
PROCEPT BioRobotics reported revenue of $308 million in fiscal 2025, 1.2 times LeMaitre Vascular's $250 million in fiscal 2025. LeMaitre Vascular's revenue grew 13.5% in its latest year, and PROCEPT BioRobotics' grew 37.2%. LeMaitre Vascular had an operating margin of 27.2%, against -33.7% at PROCEPT BioRobotics. Free cash flow was $74 million at LeMaitre Vascular and −$58 million at PROCEPT BioRobotics.
Side by side
| LeMaitre Vascular | PROCEPT BioRobotics | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $250M | $308M |
| Revenue growth | 13.5% | 37.2% |
| Revenue growth a year, last 5 years | 14.0% | 109.1% |
| Gross margin | 71.5% | 63.7% |
| Operating margin | 27.2% | −33.7% |
| Net margin | 23.1% | −31.0% |
| Free cash flow | $74M | −$58M |
| Free cash flow margin | 29.8% | −18.9% |
| Return on capital | 25.5% | −65.4% |
| Net debt to EBITDA | −2.4x | — |
| Dividends and buybacks | $20M | $0M |
| Change in diluted share count | 0.7% | 6.6% |
| Last close | $78.29 | $23.80 |
| P/E at the last close | 28.5× | — |
| Insider trades, last 12 months | sold $30.0 million | — |
| Piotroski F-score | 5 of 9 | 5 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
LeMaitre VascularPROCEPT BioRobotics
Operating margin
Percent of revenue
LeMaitre VascularPROCEPT BioRobotics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
LeMaitre VascularPROCEPT BioRobotics
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the LeMaitre Vascular and PROCEPT BioRobotics pages.